December 10, 2017
Oncopeptides presented survival data from the phase II-study O-12-M1 of Ygalo® (melflufen) at the 59th Annual Meeting of ASH today
Media
December 09, 2017
Oncopeptides presented interim data from the ongoing phase II study HORIZON with Ygalo® (melflufen) at the 59th Annual Meeting of ASH today
December 08, 2017
WILSON THERAPEUTICS HAS COMPLETED A DIRECTED SHARE ISSUE OF APPROXIMATELY SEK 244 MILLION
December 08, 2017
Invitation to conference call for updated results from the LYMRIT 37-01 Phase 1/2 trial, to be presented at ASH
December 05, 2017
GenSight Biologics reports positive long-term visual acuity gains and safety results from Phase I/II Study of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)
December 04, 2017
Nordic Nanovector to Present at Carnegie Nordic Healthcare day
December 01, 2017
Nexstim Plc Appoints Steve Beller as Vice President and General Manager, North America
November 30, 2017
Targovax ASA: New member of the board of directors
November 30, 2017
Orexo publishes prospectus and applies for listing of bonds on Nasdaq Stockholm
November 28, 2017
Onxeo Establishes Scientific Advisory Board with International Experts in DNA-targeting
